10x Genomics, Inc. — Director's Dealing 2021

May 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-03-19

Reporting Person: Saxonov Serge (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-19	Class A Common Stock	A	24571	$0.00	Acquired	905039	Direct
2021-05-24	Class A Common Stock	S	771	$162.6596	Disposed	904268	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-19	Stock Option (right to buy)	$177.76	A	61428	Acquired	2031-03-19	Class A Common Stock (61428)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	89960	Indirect

Footnotes

F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2021 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F2: The number of shares beneficially owned following the reported transaction is as of March 19, 2021.

F3: These shares were sold to cover tax withholding obligations in connection with the vesting of RSUs.

F4: The number of shares beneficially owned following the reported transaction is as of May 24, 2021.

F5: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

F6: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.